The aim of the current study was to further investigate the antitumour activity and safety profile of daily afatinib (40 mg) in previously untreated Japanese patients aged ≥75 years with EGFR mutation-positive NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.